Vertex Pharmaceuticals (VRTX) Stock Forecast, Price & News

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 6 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VRTX shares.
View VRTX analyst ratings or view top-rated stocks.

16 analysts have issued 12 month price objectives for Vertex Pharmaceuticals' shares. Their VRTX share price forecasts range from $285.00 to $456.00. On average, they expect the company's share price to reach $353.87 in the next year. This suggests a possible upside of 9.4% from the stock's current price.
View analysts price targets for VRTX or view top-rated stocks among Wall Street analysts.

Vertex Pharmaceuticals' stock was trading at $288.78 on January 1st, 2023. Since then, VRTX shares have increased by 12.0% and is now trading at $323.57.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our VRTX earnings forecast.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released its quarterly earnings results on Monday, May, 1st. The pharmaceutical company reported $3.05 earnings per share for the quarter, topping the consensus estimate of $2.51 by $0.54. The pharmaceutical company earned $2.37 billion during the quarter, compared to analysts' expectations of $2.34 billion. Vertex Pharmaceuticals had a net margin of 35.40% and a trailing twelve-month return on equity of 25.06%. Vertex Pharmaceuticals's revenue was up 13.2% on a year-over-year basis. During the same period in the previous year, the business posted $3.16 earnings per share.
Read the conference call transcript.

ETFs with the largest weight of Vertex Pharmaceuticals (NASDAQ:VRTX) stock in their portfolio include VanEck Biotech ETF (BBH), Direxion mRNA ETF (MSGR), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), Pacer US Cash Cows Growth ETF (BUL), ProShares Ultra Nasdaq Biotechnology (BIB), Invesco Dynamic Biotechnology & Genome ETF (PBE) and ProShares Nasdaq-100 Dorsey Wright Momentum ETF (QQQA).

Vertex Pharmaceuticals updated its FY 2023 earnings guidance on Monday, May, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $9.55 billion-$9.70 billion, compared to the consensus revenue estimate of $9.71 billion.

31 employees have rated Vertex Pharmaceuticals Chief Executive Officer Reshma Kewalramani on Glassdoor.com. Reshma Kewalramani has an approval rating of 76% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), Salesforce (CRM), Netflix (NFLX), Intel (INTC) and PayPal (PYPL).

Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."

Vertex Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.28%), FMR LLC (6.32%), State Street Corp (4.74%), Wellington Management Group LLP (2.92%), Price T Rowe Associates Inc. MD (2.56%) and Geode Capital Management LLC (2.10%). Insiders that own company stock include Amit Sachdev, Bastiano Sanna, Bruce I Sachs, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Joy Liu, Kristen Ambrose, Lloyd Carney, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Sangeeta N Bhatia, Stuart A Arbuckle and Yuchun Lee.
View institutional ownership trends.

Shares of VRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VRTX stock can currently be purchased for approximately $323.57.

Vertex Pharmaceuticals (NASDAQ:VRTX) has a market capitalization of $83.34 billion and generates $9.21 billion in revenue each year. The pharmaceutical company earns $3.32 billion in net income (profit) each year or $12.56 on an earnings per share basis.

The company employs 4,800 workers across the globe.

Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The official website for the company is www.vrtx.com. The pharmaceutical company can be reached via phone at (617) 341-6100, via email at investorinfo@vrtx.com, or via fax at 617-576-2109.